10 Best Undervalued Dividend Stocks Smart Money Is Buying for November 2025
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The 2025 market landscape is shaped by macroeconomic uncertainty, sector rotation, and a renewed focus on fundamentals. At ValueSense, our stock selection methodology leverages proprietary intrinsic value models, quality ratings, and deep financial analysis to identify undervalued stocks with strong growth or turnaround potential. Each pick is screened for sector diversity, financial health, and unique catalysts, ensuring a balanced and actionable watchlist for investors seeking both value and opportunity[1][2].
Featured Stock Analysis
Fortune Brands Innovations, Inc. (FBIN)
| Metric | Value |
|---|---|
| Market Cap | $6,207.8M |
| Quality Rating | 5.2 |
| Intrinsic Value | $80.4 |
| 1Y Return | -38.6% |
| Revenue | $4,489.8M |
| Free Cash Flow | $749.0M |
| Revenue Growth | (3.8%) |
| FCF margin | 16.7% |
| Gross margin | 33.5% |
| ROIC | 8.3% |
| Total Debt to Equity | 119.1% |
Investment Thesis
Fortune Brands Innovations is a diversified consumer products company with a market cap of $6.2B, specializing in home and security solutions. Despite a challenging year with a -38.6% return and revenue contraction of 3.8%, FBIN maintains robust free cash flow $749M and a healthy FCF margin 16.7%. Its intrinsic value is estimated at $80.4, suggesting potential undervaluation relative to current market sentiment.
The company's quality rating of 5.2 reflects solid operational execution, with a gross margin of 33.5% and ROIC of 8.3%. However, high leverage (total debt to equity at 119.1%) and negative recent momentum warrant careful monitoring.
Key Catalysts
- Recovery in housing and renovation markets
- Operational efficiency driving cash flow
- Potential for margin expansion through cost initiatives
Risk Factors
- Elevated debt levels may constrain flexibility
- Prolonged weakness in consumer spending
- Competitive pressures in core segments
BRF S.A. (BRFS)
| Metric | Value |
|---|---|
| Market Cap | $5,444.9M |
| Quality Rating | 7.0 |
| Intrinsic Value | $7.1 |
| 1Y Return | -23.4% |
| Revenue | R$63.9B |
| Free Cash Flow | R$9,609.4M |
| Revenue Growth | 13.1% |
| FCF margin | 15.0% |
| Gross margin | 26.3% |
| ROIC | 24.0% |
| Total Debt to Equity | 137.3% |
Investment Thesis
BRF S.A. is a leading global food company based in Brazil, with a market cap of $5.4B. The company has demonstrated strong revenue growth 13.1% and a high ROIC 24.0%, supported by a quality rating of 7.0. Its intrinsic value of $7.1 suggests room for appreciation, especially as operational improvements take hold.
Despite a -23.4% 1-year return, BRFS boasts robust free cash flow R$9.6B and a healthy FCF margin 15.0%. Gross margin stands at 26.3%, and the company is actively managing its capital structure, though total debt to equity remains high at 137.3%.
Key Catalysts
- Expansion in emerging markets and export growth
- Operational turnaround and cost optimization
- Favorable commodity price trends
Risk Factors
- Currency volatility impacting international earnings
- High leverage increases financial risk
- Exposure to agricultural input price swings
GMS Inc. (GMS)
| Metric | Value |
|---|---|
| Market Cap | $4,185.5M |
| Quality Rating | 5.6 |
| Intrinsic Value | $178.0 |
| 1Y Return | 33.4% |
| Revenue | $5,479.6M |
| Free Cash Flow | $328.6M |
| Revenue Growth | (1.1%) |
| FCF margin | 6.0% |
| Gross margin | 31.2% |
| ROIC | 5.6% |
| Total Debt to Equity | 114.1% |
Investment Thesis
GMS Inc. is a building products distributor with a $4.2B market cap, showing resilience with a 33.4% 1-year return despite a slight revenue decline -1.1%. The company’s intrinsic value is $178.0, and its quality rating is 5.6. GMS generates solid free cash flow $328.6M and maintains a gross margin of 31.2%.
The company’s FCF margin 6.0% and ROIC 5.6% reflect steady operational performance, while a total debt to equity ratio of 114.1% signals moderate leverage. GMS is well-positioned to benefit from infrastructure spending and housing market recovery.
Key Catalysts
- Increased infrastructure investment in North America
- Strategic acquisitions expanding market reach
- Margin improvement initiatives
Risk Factors
- Cyclical exposure to construction activity
- Rising interest rates affecting borrowing costs
- Competitive pricing pressures
NV5 Global, Inc. (NVEE)
| Metric | Value |
|---|---|
| Market Cap | $1,413.3M |
| Quality Rating | 6.1 |
| Intrinsic Value | $53.7 |
| 1Y Return | -5.1% |
| Revenue | $881.6M |
| Free Cash Flow | $75.4M |
| Revenue Growth | (5.5%) |
| FCF margin | 8.6% |
| Gross margin | 58.2% |
| ROIC | 3.1% |
| Total Debt to Equity | 26.7% |
Investment Thesis
NV5 Global is an engineering and consulting firm with a $1.4B market cap, focusing on infrastructure, energy, and environmental solutions. Despite a -5.1% 1-year return and revenue contraction -5.5%, NVEE maintains a strong gross margin 58.2% and a quality rating of 6.1. Its intrinsic value is $53.7.
Free cash flow is $75.4M (FCF margin 8.6%), and the company’s low debt to equity 26.7% provides financial flexibility. NVEE’s diversified service offerings and exposure to government contracts support its long-term outlook.
Key Catalysts
- Infrastructure stimulus and public sector demand
- Expansion into high-growth environmental services
- Strong balance sheet enabling strategic investments
Risk Factors
- Project delays or cancellations
- Margin compression from competitive bidding
- Slower-than-expected infrastructure spending
Couchbase, Inc. (BASE)
| Metric | Value |
|---|---|
| Market Cap | $1,340.9M |
| Quality Rating | 5.5 |
| Intrinsic Value | $48.2 |
| 1Y Return | 68.0% |
| Revenue | $220.6M |
| Free Cash Flow | ($29.5M) |
| Revenue Growth | 11.0% |
| FCF margin | (13.4%) |
| Gross margin | 87.8% |
| ROIC | (149.9%) |
| Total Debt to Equity | 6.6% |
Investment Thesis
Couchbase is a cloud database platform provider with a $1.3B market cap, delivering a standout 68.0% 1-year return. The company’s intrinsic value is $48.2, and its quality rating is 5.5. Revenue grew by 11.0% to $220.6M, with an industry-leading gross margin of 87.8%.
While Couchbase is not yet profitable (negative FCF of $29.5M and ROIC of -149.9%), its low debt to equity 6.6% and strong revenue momentum position it as a high-growth technology play.
Key Catalysts
- Adoption of cloud-native database solutions
- Expansion of enterprise customer base
- Product innovation and ecosystem growth
Risk Factors
- Ongoing operating losses and negative cash flow
- Competitive landscape in cloud data management
- Execution risk in scaling operations
SpartanNash Company (SPTN)
| Metric | Value |
|---|---|
| Market Cap | $907.8M |
| Quality Rating | 5.1 |
| Intrinsic Value | $67.1 |
| 1Y Return | 26.4% |
| Revenue | $9,693.1M |
| Free Cash Flow | $69.8M |
| Revenue Growth | 1.5% |
| FCF margin | 0.7% |
| Gross margin | 16.3% |
| ROIC | 1.7% |
| Total Debt to Equity | 142.6% |
Investment Thesis
SpartanNash is a food distribution and retail company with a $907.8M market cap. The company delivered a 26.4% 1-year return, with revenue of $9.7B and modest growth 1.5%. Its intrinsic value is $67.1, and the quality rating is 5.1.
SpartanNash’s FCF margin is low 0.7%, and gross margin stands at 16.3%. The company’s high leverage (total debt to equity 142.6%) is a concern, but its scale and distribution network provide competitive advantages.
Key Catalysts
- Expansion of private label and value offerings
- Supply chain optimization
- Growth in food distribution contracts
Risk Factors
- Thin margins and high competition
- Elevated debt levels
- Sensitivity to input cost inflation
FARO Technologies, Inc. (FARO)
| Metric | Value |
|---|---|
| Market Cap | $838.1M |
| Quality Rating | 5.6 |
| Intrinsic Value | $51.1 |
| 1Y Return | 149.4% |
| Revenue | $341.0M |
| Free Cash Flow | $22.1M |
| Revenue Growth | (4.8%) |
| FCF margin | 6.5% |
| Gross margin | 56.0% |
| ROIC | 1.6% |
| Total Debt to Equity | 30.7% |
Investment Thesis
FARO Technologies is a 3D measurement and imaging solutions provider with an $838.1M market cap. The company posted an impressive 149.4% 1-year return, reflecting strong investor sentiment. Its intrinsic value is $51.1, and the quality rating is 5.6.
Revenue declined by 4.8% to $341M, but FARO maintains a high gross margin 56.0% and positive free cash flow $22.1M. The company’s low debt to equity 30.7% supports ongoing innovation and market expansion.
Key Catalysts
- Growth in 3D metrology and digital twin adoption
- Expansion into industrial automation
- New product launches
Risk Factors
- Volatility in capital spending by customers
- Technology obsolescence risk
- Global supply chain disruptions
iTeos Therapeutics, Inc. (ITOS)
| Metric | Value |
|---|---|
| Market Cap | $442.2M |
| Quality Rating | 6.0 |
| Intrinsic Value | $12.2 |
| 1Y Return | -39.8% |
| Revenue | $0.0 |
| Free Cash Flow | ($108.7M) |
| Revenue Growth | (100.0%) |
| FCF margin | N/A |
| Gross margin | N/A |
| ROIC | (7,829.1%) |
| Total Debt to Equity | 1.0% |
Investment Thesis
iTeos Therapeutics is a clinical-stage biotech company with a $442.2M market cap, focused on immuno-oncology. The company’s 1-year return is -39.8%, and it currently generates no revenue. Its intrinsic value is $12.2, and the quality rating is 6.0.
iTeos has a strong cash position but negative free cash flow -$108.7M and an extremely high negative ROIC -7,829.1%. With minimal debt (total debt to equity 1.0%), the company is positioned to advance its pipeline, but faces significant execution risk.
Key Catalysts
- Progress in clinical trial milestones
- Strategic partnerships or licensing deals
- Advancements in immunotherapy research
Risk Factors
- Clinical and regulatory uncertainty
- Ongoing operating losses
- High R&D burn rate
Blade Air Mobility, Inc. (BLDE)
| Metric | Value |
|---|---|
| Market Cap | $414.6M |
| Quality Rating | 4.8 |
| Intrinsic Value | $5.7 |
| 1Y Return | 78.9% |
| Revenue | $254.3M |
| Free Cash Flow | ($19.5M) |
| Revenue Growth | 6.7% |
| FCF margin | (7.7%) |
| Gross margin | 24.4% |
| ROIC | (20.8%) |
| Total Debt to Equity | 4.0% |
Investment Thesis
Blade Air Mobility is a technology-powered air mobility platform with a $414.6M market cap. The company delivered a 78.9% 1-year return, with revenue up 6.7% to $254.3M. Its intrinsic value is $5.7, and the quality rating is 4.8.
Blade is not yet profitable (negative FCF of $19.5M, ROIC -20.8%), but maintains a low debt to equity 4.0%. The company’s gross margin is 24.4%, and it is well-positioned to benefit from urban mobility trends.
Key Catalysts
- Expansion of urban air mobility services
- Strategic partnerships and route expansion
- Regulatory progress in air mobility
Risk Factors
- High cash burn and negative margins
- Regulatory and operational hurdles
- Competition from traditional and emerging transport modes
Vasta Platform Limited (VSTA)
| Metric | Value |
|---|---|
| Market Cap | $393.0M |
| Quality Rating | 6.6 |
| Intrinsic Value | $7.1 |
| 1Y Return | 88.5% |
| Revenue | R$1,708.0M |
| Free Cash Flow | R$170.6M |
| Revenue Growth | 9.0% |
| FCF margin | 10.0% |
| Gross margin | 60.2% |
| ROIC | 7.6% |
| Total Debt to Equity | 23.9% |
Investment Thesis
Vasta Platform is a Brazilian education technology company with a $393M market cap. The company posted an 88.5% 1-year return, with revenue growth of 9.0% R$1.7B. Its intrinsic value is $7.1, and the quality rating is 6.6.
Vasta’s free cash flow is R$170.6M (FCF margin 10.0%), and it boasts a high gross margin 60.2% with moderate leverage (total debt to equity 23.9%). The company is positioned to benefit from digital transformation in education.
Key Catalysts
- Growth in digital education adoption in Brazil
- Expansion of content and platform offerings
- Strategic partnerships with educational institutions
Risk Factors
- Regulatory changes in education sector
- Currency and macroeconomic volatility
- Competition from global edtech providers
Portfolio Diversification Insights
This watchlist spans multiple sectors—including technology, healthcare, industrials, consumer, and education—providing a diversified exposure to both growth and value opportunities. The inclusion of companies from North America, Brazil, and global markets further enhances geographic diversification. By balancing high-growth technology stocks (BASE, BLDE), stable cash generators (FBIN, GMS), and turnaround plays (BRFS, ITOS), the portfolio aims to mitigate sector-specific risks while capturing upside from varied market drivers.
Market Timing & Entry Strategies
Given the volatility in 2025, staggered entry and dollar-cost averaging may help manage risk. Investors may consider monitoring technical support levels, earnings reports, and macroeconomic indicators before initiating or adding to positions. For high-growth or speculative names, position sizing and stop-loss strategies can help manage downside risk. ValueSense’s intrinsic value tools and backtesting features can further inform entry points and portfolio construction[1][2].
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- How VKTX (Viking Therapeutics) Makes Money in 2025: A Deep-Dive With Income Statement
- How NET (Cloudflare) Makes Money in 2025: A Deep-Dive With Income Statement
- How MASS (908 Devices) Makes Money in 2025: A Deep-Dive With Income Statement
- How CRVO (CervoMed) Makes Money in 2025: A Deep-Dive With Income Statement
- How GILD (Gilead Sciences) Makes Money in 2025: A Deep-Dive With Income Statement
FAQ Section
Q1: How were these stocks selected?
Stocks were chosen using ValueSense’s proprietary intrinsic value models, quality ratings, and a multi-factor screening process that emphasizes undervaluation, financial health, and sector diversification[1][2].
Q2: What's the best stock from this list?
Each stock serves a different investment profile; high-growth options like FARO and VSTA offer momentum, while BRFS and FBIN provide value and turnaround potential. The “best” depends on individual risk tolerance and portfolio goals.
Q3: Should I buy all these stocks or diversify?
Diversification across sectors and geographies can help manage risk. This watchlist is designed to provide a balanced mix, but allocation should reflect your own investment objectives and risk profile.
Q4: What are the biggest risks with these picks?
Key risks include sector-specific headwinds, high leverage for some companies, ongoing operating losses for growth names, and macroeconomic volatility. Each stock’s risk profile is detailed in its analysis section.
Q5: When is the best time to invest in these stocks?
Optimal timing depends on market conditions, company-specific news, and valuation levels. Using tools like ValueSense’s intrinsic value calculator and monitoring earnings releases can help inform entry points[1][2].